582 studies found for:    Open Studies | "Leukemia, Myeloid, Acute"
Show Display Options
Rank Status Study
21 Recruiting Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: tretinoin;   Drug: lithium carbonate;   Other: laboratory biomarker analysis
22 Recruiting MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: MEK inhibitor MEK162;   Drug: idarubicin;   Drug: cytarabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
23 Recruiting Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Sirolimus;   Drug: Idarubicin;   Drug: Cytarabine
24 Recruiting Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Daunorubicin Hydrochloride;   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
25 Recruiting Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: Filgrastim;   Drug: Mitoxantrone Hydrochloride;   Drug: Cladribine;   Drug: Cytarabine
26 Recruiting Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: lenalidomide;   Drug: mitoxantrone hydrochloride;   Drug: etoposide;   Drug: cytarabine
27 Recruiting Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Idarubicin;   Drug: Vorinostat;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
28 Recruiting Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Promyelocytic Leukemia (M3);   Childhood Acute Promyelocytic Leukemia (M3);   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia
Interventions: Drug: gemtuzumab ozogamicin;   Other: laboratory biomarker analysis
29 Recruiting Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Drug: daunorubicin hydrochloride;   Other: clinical observation;   Drug: cytarabine;   Drug: decitabine;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
30 Not yet recruiting Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: cyclophosphamide;   Biological: anti CD123-CAR/CD28-costimulatory, retroviral vector-transduced autologous T lymphocytes;   Other: laboratory biomarker analysis
31 Recruiting Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: decitabine;   Drug: cytarabine
32 Recruiting Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Radiation: iodine I 131 monoclonal antibody BC8;   Procedure: allogeneic bone marrow transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
33 Recruiting CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: CPI-613;   Drug: cytarabine;   Drug: mitoxantrone hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
34 Recruiting Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Myelodysplastic Syndrome With Isolated Del(5q);   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: Sirolimus;   Drug: Azacitidine
35 Unknown  Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia
Condition: Leukemia, Myeloid, Acute
Intervention: Procedure: Allogenic transplantation
36 Not yet recruiting Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia
Interventions: Biological: Nivolumab;   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis
37 Not yet recruiting SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: SGI-110 (guadecitabine);   Drug: Treatment Choice
38 Recruiting Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: 300 mg Oral Azacitidine;   Drug: Placebo
39 Recruiting Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: Human Stem Cell Transplantation;   Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
40 Recruiting Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Intervention: Drug: Oral Azacitidine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years